Search clinical trials for: Dalfampridine-ER 5mg

Total 12966 results

Acorda Therapeutics

Completed

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Multiple Sclerosis

United States
Acorda Therapeutics

Terminated

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine. (MILESTONE℠)

Post-ischemic Stroke

United States, Canada
Acorda Therapeutics

Completed

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

Ischemic Stroke

United States
Acorda Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets. (MILESTONE℠)

Post-Ischemic Stroke

United States, Canada
Acorda Therapeutics

Completed

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

Renal Insufficiency

United States
Ain Shams University

Recruiting

Dalfampridine in Egyptian Patients With Multiple Sclerosis

Multiple Sclerosis

Egypt
Acorda Therapeutics

Completed

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Cerebral Palsy (CP)

United States
Columbia University

Completed

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

Spinal Muscular Atrophy

United States
Acorda Therapeutics
Prometrika, LLC; BCS Consulting, Inc.

Completed

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Brown, Theodore R., M.D., MPH
Acorda Therapeutics

Completed

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Multiple Sclerosis

United States
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Biogen
Acorda Therapeutics

Completed

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Multiple Sclerosis

Canada
GlaxoSmithKline

Completed

A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)

Asthma

Germany, South Africa, Bulgaria
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Zogenix, Inc.

Completed

A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery

Postoperative Pain
Kowa Company, Ltd.

Completed

A Phase III Long Term Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
Kowa Company, Ltd.

Completed

A Phase III Confirmatory Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
MGH Institute of Health Professions

Not yet recruiting

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis (AmpPT)

Multiple Sclerosis

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Healthy
Biogen

Completed

Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (MOBILE)

Multiple Sclerosis

Sweden, United Kingdom, Netherlands, Belgium, Canada, Italy
Washington University School of Medicine
Acorda Therapeutics

Completed

Ampyra for Optic Neuritis in Multiple Sclerosis

Multiple Sclerosis | Optic Neuritis

United States
University of Edinburgh
NHS Lothian

Completed

Cardiovascular Effects of Apelin In Healthy Volunteers

Healthy

United Kingdom
Pfizer

Completed

BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG

Neurogenic Detrusor Overactivity

Belgium
Genor Biopharma Co., Ltd.

Unknown

Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

Rheumatoid Arthritis

China
Buddhist Tzu Chi General Hospital

Completed

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

Overactive Bladder

Taiwan
Impax Laboratories, LLC

Completed

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Estonia, Latvia, Ukraine
Trevi Therapeutics

Recruiting

Cough Reduction in IPF With Nalbuphine ER (CORAL)

Idiopathic Pulmonary Fibrosis

United Kingdom, Australia, Netherlands, Italy, Spain, Poland, Turkey, Canada, Chile, Germany
UCB Biopharma SRL

Active, not recruiting

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Generalized Myasthenia Gravis

United States, Canada, Georgia, Germany, Italy, Japan, Poland, Serbia, Spain, United Kingdom
Hanmi Pharmaceutical Company Limited

Completed

Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet (PGP inhibitor)

Healthy

Korea, Republic of
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Samsung Medical Center
Pfizer

Completed

Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder

Overactive Bladder

Korea, Republic of
Institut de Recherches Internationales Servier

Completed

Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms

Alzheimer's Disease

Brazil, South Africa, Chile, Hungary, Bulgaria, Czechia, Germany, Japan, Mexico, Poland, Russian Federation, Slovakia
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

China
Rhode Island Hospital

Completed

Improving Emotion Regulation Skills Among Adolescents Attempting to Lose Weight

Overweight and Obesity

United States
Columbia University
Biolase Inc

Active, not recruiting

Peri-implantitis Treatment: Clinical Results of Conventional Treatment vs. the Addition of Biolase

Peri-Implantitis

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Impax Laboratories, LLC

Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease (APEX-PD)

Parkinson's Disease

United States, Canada, Estonia, Latvia, Lithuania, Romania, Ukraine
Uppsala University

Recruiting

Emotion Regulation Training for Adolescents With ADHD

ADHD | Emotion Regulation | Attention Deficit Disorder With Hyperactivity

Sweden
Jewish General Hospital

Recruiting

Emergency Room Visits and Older Patients (ER2) (ER2)

Emergencies | Length of Stay

Canada
Medical University of South Carolina
Georgia State University

Completed

PTSD Treatment and Emotion Regulation Skills Training for Veterans With Military Sexual Trauma (PE+ER) (PE+ER)

Anxiety Disorders | Stress Disorders, Post-Traumatic | Mental Disorder | Traumatic Stress Disorder

United States
HealthPartners Institute

Terminated

Outreach-ER: A Dementia Care Intervention Program

Dementia

United States
Helixmith Co., Ltd.

Completed

Safety Study of Gene Therapy in Treating Lower Leg Ischemia

Critical Limb Ischemia

United States
Asieris Pharmaceuticals (AUS) Pty Ltd.

Completed

A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

Bladder Cancer

Australia
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers

Healthy Volunteer

China
European University of Lefke

Completed

Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

Hereditary Spastic Paraplegia

Cyprus
Ultragenyx Pharmaceutical Inc

Completed

An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy

GNE Myopathy | Hereditary Inclusion Body Myopathy (HIBM)

United States, Israel
Member Companies of the Opioid PMR Consortium

Terminated

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

Opioid-Related Disorders | Drug Abuse | Opiate Addiction | Narcotic Abuse

United States
UCB Biopharma SRL

Not yet recruiting

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis (roMyG)

Generalized Myasthenia Gravis

3

Subscribe